Skip to main content
Commentary: Newer Drugs for AD Plus Dupilumab and Other Issues, September 2023
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Commentary: Newer Drugs for AD Plus Dupilumab and Other Issues, September 2023
User login
Username
Password
Reset your password
Concept
Lead
score
Dermatitis
1
1
Atopic Dermatitis
0
0.95
Skin Care
0
0.75
Child
0
0.55
Steroids
0
0.12
Biologic Therapy
0
0.95
Monoclonal Antibody
0
0.95
Sarcoma
0
0.07
Adherence
0
0.55
Interleukin
0
0.75
Specialty
Lead
score
Dermatology
1
1
Family Medicine/Primary Care
0
1
Pediatrics
0
0.66
Pharmacist
0
0.6
Edit Tags